<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039364</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16011-26013</org_study_id>
    <secondary_id>EORTC-16011</secondary_id>
    <secondary_id>EORTC-26013</secondary_id>
    <nct_id>NCT00039364</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Gliomas</brief_title>
  <official_title>Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth&#xD;
      of the tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients&#xD;
      who have gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the therapeutic activity of imatinib mesylate (in terms of objective response&#xD;
           and progression-free survival at 6 months) in patients with gliomas.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to glioma&#xD;
      (glioblastoma multiforme vs anaplastic oligodendroglioma or mixed oligoastrocytoma vs&#xD;
      anaplastic astrocytoma or recurrent low-grade astrocytoma).&#xD;
&#xD;
      Patients receive oral imatinib mesylate once or twice daily. Treatment repeats every 4 weeks&#xD;
      for up to 9 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 6 months and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 77 patients (29 patients with glioblastoma multiforme, 24&#xD;
      patients with anaplastic oligodendroglioma or mixed oligoastrocytoma, and 24 patients with&#xD;
      anaplastic astrocytoma or recurrent low-grade astrocytoma) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">112</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed glioblastoma multiforme&#xD;
&#xD;
               -  Recurrent disease by CT scan or MRI&#xD;
&#xD;
               -  No prior chemotherapy OR&#xD;
&#xD;
               -  No more than 1 prior chemotherapy regimen in adjuvant setting or for recurrent&#xD;
                  disease OR&#xD;
&#xD;
          -  Histologically or cytologically confirmed anaplastic oligodendroglioma, mixed&#xD;
             oligoastrocytoma, anaplastic astrocytoma, or recurrent low-grade astrocytoma&#xD;
&#xD;
               -  Failed prior radiotherapy&#xD;
&#xD;
               -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
                    -  Failed adjuvant chemotherapy OR&#xD;
&#xD;
                    -  Failed first-line chemotherapy&#xD;
&#xD;
          -  At least 1 bidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 2 cm on contrast-enhanced CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac function normal&#xD;
&#xD;
          -  No ischemic heart disease within the past 6 months&#xD;
&#xD;
          -  Normal 12-lead ECG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except cone-biopsied carcinoma of the cervix&#xD;
             or adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No unstable systemic disease&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
          -  No concurrent cytokines (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Must be on stable or decreasing dose of corticosteroids for at least 2 weeks&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior brain irradiation&#xD;
&#xD;
          -  No prior high-dose radiotherapy (more than 65 Gy), stereotactic radiosurgery, or&#xD;
             internal radiotherapy unless the recurrence is histologically confirmed&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery for primary brain tumor within the past 3 months allowed provided one of&#xD;
             the following conditions are present:&#xD;
&#xD;
               -  Postoperative imaging within 72 hours after surgery shows a clearly limited&#xD;
                  target lesion of at least 2 cm&#xD;
&#xD;
               -  Postoperative follow-up shows a progressive and measurable target lesion&#xD;
&#xD;
               -  A second measurable target lesion is present outside the surgical area&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent warfarin or other anticoagulants&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Raymond, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin J. van Den Bent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer, Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson Oncology Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ; European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008 Oct 1;26(28):4659-65. doi: 10.1200/JCO.2008.16.9235.</citation>
    <PMID>18824712</PMID>
  </results_reference>
  <results_reference>
    <citation>Raymond E, Brandes A, Van Oosterom A, et al.: Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup study. [Abstract] J Clin Oncol 22 (Suppl 14): A-1501, 2004.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

